Sight Sciences SEC filings document the company’s ophthalmic medical device business, segment operating results, governance, capital structure, and material events. Form 8-K filings report quarterly and annual financial results, investor presentation materials, and Regulation FD disclosures tied to the company’s Interventional Glaucoma and Interventional Dry Eye operations.
The filing record also includes definitive proxy materials for annual meeting matters, disclosures on executive officer changes and compensatory arrangements, material agreements such as lease amendments, and legal disclosures involving interventional glaucoma patents. These filings frame SGHT’s public reporting around product commercialization, intellectual property, corporate governance, risk factors, and shareholder voting matters.
Sight Sciences Chief Legal Officer Jeremy B. Hayden reported selling 6,308 shares of the company’s common stock on January 16, 2026 at a weighted average price of $6.62 per share. The shares were sold to cover his tax liability arising from the vesting of restricted stock units, rather than as a discretionary open-market sale. Following this transaction, he beneficially owns 267,611 shares, consisting of 75,562 shares of common stock and 192,049 shares that will be received upon vesting and settlement of unvested RSUs. The filing also clarifies prior reporting by adding 39,825 previously omitted RSU shares and removing 11,326 stock option shares that had been inadvertently included in an earlier balance.
BlackRock, Inc. has filed a Schedule 13G reporting a passive ownership stake in Sight Sciences, Inc. common stock. As of the event date of December 31, 2025, BlackRock reports beneficial ownership of 2,651,156 shares, representing 5.01% of Sight Sciences’ outstanding common stock.
BlackRock reports sole voting power over 2,614,209 shares and sole dispositive power over 2,651,156 shares, with no shared voting or dispositive power. The filing notes that various underlying persons have rights to dividends or sale proceeds in the ordinary course, but no single person has more than five percent of the total outstanding common shares.
BlackRock certifies that the shares were acquired and are held in the ordinary course of business, and not for the purpose of changing or influencing control of Sight Sciences, consistent with a passive institutional investment.
A shareholder has filed a Form 144 notice to sell SGHT common stock. The notice covers a proposed sale of 2,616 shares of common stock through Fidelity Brokerage Services LLC on or about 01/16/2026 on the NASDAQ market, with an aggregate market value of 17,310.86. The issuer has 52,871,731 shares of this class outstanding.
The 2,616 shares to be sold were acquired on 01/15/2026 via restricted stock vesting from the issuer as compensation. The person named, James Rodberg, has also sold common shares of the same issuer during the past three months, including 2,518 shares on 12/02/2025 for gross proceeds of 20,782.06, 4,405 shares on 01/05/2026 for 34,460.31, and 594 shares on 01/06/2026 for 4,444.07.
A shareholder of SGHT filed a Rule 144 notice to sell 4,836 shares of common stock, with an aggregate market value of $32,001.26, through Fidelity Brokerage Services on the NASDAQ around 01/16/2026. The filing indicates there were 52,871,731 common shares outstanding at the time this notice was prepared, which is a separate baseline figure.
The 4,836 shares were acquired on 01/15/2026 via restricted stock vesting from the issuer as compensation, with payment also dated 01/15/2026. Over the prior three months, the same seller, David Y. Badawi, reported additional common stock sales of 2,914 shares for $21,654.23, 3,051 shares for $23,867.97, and 3,695 shares for $27,644.51. By signing the notice, the seller represents that he is not aware of any undisclosed material adverse information about the issuer’s operations.
Sight Sciences insider transaction: A notice has been filed to sell 6,308 shares of common stock of Sight Sciences through Fidelity Brokerage Services LLC on or about 01/16/2026, with the shares listed on NASDAQ. The shares relate to restricted stock that vested on 01/15/2026, acquired from the issuer as compensation.
As context, the notice reports 52,871,731 shares of common stock outstanding. It also lists prior sales during the past three months by Jeremy Hayden, including 3,150 shares sold on 11/12/2025 for gross proceeds of 25,227.78, 44,850 shares sold on 11/25/2025 for 362,596.77, 9,385 shares sold on 01/05/2026 for 73,418.85, and 1,785 shares sold on 01/06/2026 for 13,354.66.
A shareholder filed a Rule 144 notice to sell 9,748 common shares, with an aggregate market value of $64,141.84, through Fidelity Brokerage Services on the NASDAQ market. The shares relate to stock options that were granted on January 9, 2020 and May 11, 2020 and were acquired and paid for in cash on January 16, 2026.
Over the prior three months, the same seller, Erica Rogers, reported additional common stock sales, including 20,000 shares for $172,804.00 on December 29, 2025 and 20,000 shares for $132,034.00 on January 15, 2026, along with two smaller transactions. The filer certifies they are not aware of undisclosed material adverse information about the issuer’s current or prospective operations.
A shareholder filed a Form 144 notice to sell 20,000 shares of common stock through Fidelity Brokerage Services LLC on NASDAQ, with an aggregate market value of 132,034.24.
The filing states that 52,871,731 shares of this class were outstanding and that the planned sale is expected around 01/15/2026.
The 20,000 shares come from stock options granted on 01/09/2020 and 05/11/2020, each for 10,000 shares, acquired and paid for in cash on 01/15/2026. Over the prior three months, Erica Rogers sold additional blocks of common stock totaling 40,252 shares, with gross proceeds of 172,804.00, 84,223.26, and 73,781.00.
Sight Sciences, Inc. filed a current report to let investors know it has released preliminary, unaudited financial results. On January 13, 2026, the company issued a press release with selected results for the fourth quarter and full year ended December 31, 2025. That press release is included as Exhibit 99.1 to this Form 8-K under the section covering results of operations and financial condition. The company states that this information, including the exhibit, is being furnished rather than filed, which limits how it is treated under securities law and how it may be incorporated into other SEC filings.
SGHT filed a notice under Rule 144 for a planned sale of 10,000 shares of common stock through Fidelity Brokerage Services LLC on 01/12/2026, listed with an aggregate market value of 73,781.43 and referencing 52,871,731 shares outstanding and NASDAQ as the exchange.
The shares to be sold were acquired on 01/12/2026 via an option originally granted on 05/11/2020, with cash as the form of payment. The notice lists prior sales for the same account holder, Erica Rogers, including 20,000 common shares sold on 12/29/2025 for gross proceeds of 172,804.00 and 10,252 common shares sold on 12/30/2025 for gross proceeds of 84,223.26. By signing, the seller represents that they are not aware of any undisclosed material adverse information about the issuer’s operations.